News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Metastatix, Inc. Granted Investigational New Drug (IND) Application for MSX-122


11/6/2007 12:31:38 PM

ATLANTA--(BUSINESS WIRE)--Metastatix, Inc., an emerging pharmaceutical company focused on the development of small molecule therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for MSX-122, a potent CXCR4 inhibitor that the company is developing for the treatment of a number of critical indications, including various cancers and inflammatory diseases. The IND acceptance will permit Metastatix to commence Phase I clinical studies in the U.S. to determine the safety and tolerability of MSX-122 for the treatment of solid tumors.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES